Adv Ther (2017) 34:1936–1952 DOI 10.1007/s12325-017-0578-8 ORIGINAL RESEARCH Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy . . . . Wenhui Wei Keith Knapp Li Wang Chieh-I Chen . . Gary L. Craig Karen Ferguson Sergio Schwartzman Received: April 26, 2017 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication cycled to a TNFi or switched to a new MOA ABSTRACT therapy by March 2015. Cox proportional haz- ards models were used for time to non-persis- Introduction: To examine treatment persis- tence (switching or discontinuing). An ordinary tence and clinical outcomes associated with least squares regression model compared 1-year switching from a tumor necrosis factor inhibitor reduction from baseline for the Clinical Disease (TNFi) to a medication with a new mechanism Activity Index (CDAI). of action (MOA) (abatacept, anakinra, ritux- Results: There were 332 (54.2%) TNFi cyclers imab, tocilizumab, or tofacitinib) versus cycling and 281 (45.8%) new MOA switchers. During a to another TNFi (adalimumab, certolizumab median follow-up of 29.9 months, treatment
Advances in Therapy – Springer Journals
Published: Jul 3, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera